RecruitingPHASE1, PHASE2NCT07185269

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

Studying Systemic lupus erythematosus

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Intervention
626(drug)
Enrollment
198 enrolled
Eligibility
18-70 years · All sexes
Timeline
20252028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07185269 on ClinicalTrials.gov

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Systemic lupus erythematosus

← Back to all trials